GU Cancers 2024 | Which patients with prostate cancer benefit from radiotherapy and hormonal therapy?

Alan Dal Pra, MD, University of Miami, Miami, FL, comments on the role of extended hormonal therapy and radiotherapy in patients with prostate cancer. The RTOG 9601 trial (NCT00002874) of salvage radiation therapy with two years of placebo or bicalutamide initially demonstrated overall survival benefit in patients receiving bicalutamide. However, subsequent studies showed that patients with lower PSA had a higher risk of mortality. The RADICALS-HD trial (ISRCTN40814031) of radiotherapy with either 6 or 24 months of androgen-deprivation therapy additionally demonstrated that metastasis-free survival was improved in the latter cohort. This interview took place at the ASCO GU Cancers Symposium 2024 in San Francisco, CA.

These works are owned by Magdalen Medical Publishing (MMP) and are protected by copyright laws and treaties around the world. All rights are reserved.